Laia Foradada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laia Foradada has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Massó-Vallés
Peptomyc S.L., Barcelona, Spain
4 shared publications - Laura Soucek
Models of Cancer Therapies Group, Vall d’Hebron Institute of Oncology (VHIO), Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH), Vall d’Hebron Barcelona Hospital Campus
4 shared publications - Jonathan R. Whitfield
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
3 shared publications - Mariano Federico Zacarías-Fluck
Vall d'Hebron Institute of Oncology Cellex Centre Hospital University Vall d'Hebron Campus Barcelona Spain
3 shared publications - Marie-Eve Beaulieu
Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
3 shared publications - Martí Pumarola
Mouse and Comparative Pathology Unit, Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine Universitat Autònoma de Barcelona Barcelona Spain
3 shared publications
Latest Publications
- Open Access
- 1 April 2023
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 37 (7-8) , 303-320
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.
- 1 April 2023
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 37 (7-8) , 303-320
Open AccessReducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.
- Open Access
Engineering pH‐Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics
MicroRNAs (miRNAs) are small non‐coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non‐liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor‐suppressive response is reported. The engineered pH‐sensitive nanovesicles have controlled structure (unilamellar), size (24 weeks), and are prepared by a green, GMP compliant, and scalable one‐step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics.
Open AccessEngineering pH‐Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics
MicroRNAs (miRNAs) are small non‐coding endogenous RNAs, which are attracting a growing interest as therapeutic molecules due to their central role in major diseases. However, the transformation of these biomolecules into drugs is limited due to their unstability in the bloodstream, caused by nucleases abundantly present in the blood, and poor capacity to enter cells. The conjugation of miRNAs to nanoparticles (NPs) could be an effective strategy for their clinical delivery. Herein, the engineering of non‐liposomal lipid nanovesicles, named quatsomes (QS), for the delivery of miRNAs and other small RNAs into the cytosol of tumor cells, triggering a tumor‐suppressive response is reported. The engineered pH‐sensitive nanovesicles have controlled structure (unilamellar), size (24 weeks), and are prepared by a green, GMP compliant, and scalable one‐step procedure, which are all unavoidable requirements for the arrival to the clinical practice of NP based miRNA therapeutics. Furthermore, QS protect miRNAs from RNAses and when injected intravenously, deliver them into liver, lung, and neuroblastoma xenografts tumors. These stable nanovesicles with tunable pH sensitiveness constitute an attractive platform for the efficient delivery of miRNAs and other small RNAs with therapeutic activity and their exploitation in the clinics.
- 27 October 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (7) , 2101544
In Vivo Antitumor and Antimetastatic Efficacy of a Polyacetal‐Based Paclitaxel Conjugate for Prostate Cancer Therapy
Prostate cancer (PCa), one of the leading causes of cancer‐related deaths, currently lacks effective treatment for advanced‐stage disease. Paclitaxel (PTX) is a highly active chemotherapeutic drug and the first‐line treatment for PCa; however, conventional PTX formulation causes severe hypersensitivity reactions and limits PTX use at high concentrations. In the pursuit of high molecular weight, biodegradable, and pH‐responsive polymeric carriers, one conjugates PTX to a polyacetal‐based nanocarrier to yield a tert‐Ser‐PTX polyacetal conjugate. tert‐Ser‐PTX conjugate provides sustained release of PTX over 2 weeks in a pH‐responsive manner while also obtaining a degree of epimerization of PTX to 7‐epi‐PTX. Serum proteins stabilize tert‐Ser‐PTX, with enhanced stability in human serum versus PBS (pH 7.4). In vitro efficacy assessments in PCa cells demonstrate IC50 values above those for the free form of PTX due to the differential cell trafficking modes; however, in vivo tolerability assays demonstrate that tert‐Ser‐PTX significantly reduces the systemic toxicities associated with free PTX treatment. tert‐Ser‐PTX also effectively inhibits primary tumor growth and hematologic, lymphatic, and coelomic dissemination, as confirmed by in vivo and ex vivo bioluminescence imaging and histopathological evaluations in mice carrying orthotopic LNCaP tumors. Overall, the results suggest the application of tert‐Ser‐PTX as a robust antitumor/antimetastatic treatment for PCa.
- 27 October 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (7) , 2101544
In Vivo Antitumor and Antimetastatic Efficacy of a Polyacetal‐Based Paclitaxel Conjugate for Prostate Cancer Therapy
Prostate cancer (PCa), one of the leading causes of cancer‐related deaths, currently lacks effective treatment for advanced‐stage disease. Paclitaxel (PTX) is a highly active chemotherapeutic drug and the first‐line treatment for PCa; however, conventional PTX formulation causes severe hypersensitivity reactions and limits PTX use at high concentrations. In the pursuit of high molecular weight, biodegradable, and pH‐responsive polymeric carriers, one conjugates PTX to a polyacetal‐based nanocarrier to yield a tert‐Ser‐PTX polyacetal conjugate. tert‐Ser‐PTX conjugate provides sustained release of PTX over 2 weeks in a pH‐responsive manner while also obtaining a degree of epimerization of PTX to 7‐epi‐PTX. Serum proteins stabilize tert‐Ser‐PTX, with enhanced stability in human serum versus PBS (pH 7.4). In vitro efficacy assessments in PCa cells demonstrate IC50 values above those for the free form of PTX due to the differential cell trafficking modes; however, in vivo tolerability assays demonstrate that tert‐Ser‐PTX significantly reduces the systemic toxicities associated with free PTX treatment. tert‐Ser‐PTX also effectively inhibits primary tumor growth and hematologic, lymphatic, and coelomic dissemination, as confirmed by in vivo and ex vivo bioluminescence imaging and histopathological evaluations in mice carrying orthotopic LNCaP tumors. Overall, the results suggest the application of tert‐Ser‐PTX as a robust antitumor/antimetastatic treatment for PCa.
- 20 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (484)
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
We demonstrate the pharmacologic potential of the purified cell-penetrating Omomyc mini-protein to directly inhibit MYC function in vitro and in vivo.
- 20 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (484)
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
We demonstrate the pharmacologic potential of the purified cell-penetrating Omomyc mini-protein to directly inhibit MYC function in vitro and in vivo.
- Open Access
- 10 April 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (27) , 18734-18746
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
- 10 April 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (27) , 18734-18746
Open AccessBET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
- 1 February 2018
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 14 (2) , 257-267
Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles
- 1 February 2018
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 14 (2) , 257-267
Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles
- Open Access
- 14 April 2016
- Published by IOP Publishing in Biofabrication
- Vol. 8 (2) , 025001
Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria
Biofabrication is attracting interest as a means to produce nanostructured functional materials because of its operational versatility and full scalability. Materials based on proteins are especially appealing, as the structure and functionality of proteins can be adapted by genetic engineering. Furthermore, strategies and tools for protein production have been developed and refined steadily for more than 30 years. However, protein conformation and therefore activity might be sensitive to production conditions. Here, we have explored whether the downstream strategy influences the structure and biological activities, in vitro and in vivo, of a self-assembling, CD44-targeted protein-only nanoparticle produced in Escherichia coli. This has been performed through the comparative analysis of particles built from soluble protein species or protein versions obtained by in vitro protein extraction from inclusion bodies, through mild, non-denaturing procedures. These methods have been developed recently as a convenient alternative to the use of toxic chaotropic agents for protein resolubilization from protein aggregates. The results indicate that the resulting material shows substantial differences in its physicochemical properties and its biological performance at the systems level, and that its building blocks are sensitive to the particular protein source.
- 14 April 2016
- Published by IOP Publishing in Biofabrication
- Vol. 8 (2) , 025001
Open AccessConformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria
Biofabrication is attracting interest as a means to produce nanostructured functional materials because of its operational versatility and full scalability. Materials based on proteins are especially appealing, as the structure and functionality of proteins can be adapted by genetic engineering. Furthermore, strategies and tools for protein production have been developed and refined steadily for more than 30 years. However, protein conformation and therefore activity might be sensitive to production conditions. Here, we have explored whether the downstream strategy influences the structure and biological activities, in vitro and in vivo, of a self-assembling, CD44-targeted protein-only nanoparticle produced in Escherichia coli. This has been performed through the comparative analysis of particles built from soluble protein species or protein versions obtained by in vitro protein extraction from inclusion bodies, through mild, non-denaturing procedures. These methods have been developed recently as a convenient alternative to the use of toxic chaotropic agents for protein resolubilization from protein aggregates. The results indicate that the resulting material shows substantial differences in its physicochemical properties and its biological performance at the systems level, and that its building blocks are sensitive to the particular protein source.
- 15 June 2012
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 53 (6) , 655-659
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FINDINGS OF AN INTRACRANIAL EPIDURAL TUBERCULOMA IN A DOG
- 15 June 2012
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 53 (6) , 655-659
IMAGING DIAGNOSIS-MAGNETIC RESONANCE IMAGING FINDINGS OF AN INTRACRANIAL EPIDURAL TUBERCULOMA IN A DOG
- 24 September 2010
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 52 (1) , 17-24
CLINICAL, PATHOLOGIC, AND MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF CANINE DISC EXTRUSION ACCOMPANIED BY EPIDURAL HEMORRHAGE OR INFLAMMATION
Our aim was to characterize the magnetic resonance (MR) imaging features of canine disc extrusion accompanied by epidural hemorrhage or inflammation. We correlated the imaging characteristics of this type of disc extrusion in 46 dogs and compared these features with clinical signs and pathologic findings. Data from 50 control dogs with MR imaging features of a disc extrusion with no associated hemorrhage or inflammation, characterized by a T2‐hypointense extradural mass, were used for comparison of the relative location of the two types of lesions and prognosis. Disc extrusion causing epidural hemorrhage or inflammation is more common in the caudal aspect of the lumbar spine than disc extrusions that do not cause signs of hemorrhage or inflammation (P<0.05) in MR images. In dogs with disc extrusion and associated epidural hemorrhage or inflammation, there was no association between MR imaging features and signalment, the presence or absence of hemorrhage, or pathologic findings. The appearance of the lesion created by disc extrusion with epidural hemorrhage and inflammation encompasses a wide variety of imaging features, likely related to the duration of the hemorrhage and associated inflammatory changes. In 10 of 46 dogs these secondary changes masked identification of the disc extrusion itself in the MR images. An awareness of the variety of MR imaging features of disc extrusion accompanied by extradural hemorrhage or inflammation is important to avoid making an incorrect diagnosis and to facilitate a proper surgical approach. The prognosis of dogs with disc extrusion accompanied by hemorrhage or inflammation does not appear to be different than for dogs with disc extrusion and without imaging signs of epidural hemorrhage or inflammation.
- 24 September 2010
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 52 (1) , 17-24
CLINICAL, PATHOLOGIC, AND MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF CANINE DISC EXTRUSION ACCOMPANIED BY EPIDURAL HEMORRHAGE OR INFLAMMATION
Our aim was to characterize the magnetic resonance (MR) imaging features of canine disc extrusion accompanied by epidural hemorrhage or inflammation. We correlated the imaging characteristics of this type of disc extrusion in 46 dogs and compared these features with clinical signs and pathologic findings. Data from 50 control dogs with MR imaging features of a disc extrusion with no associated hemorrhage or inflammation, characterized by a T2‐hypointense extradural mass, were used for comparison of the relative location of the two types of lesions and prognosis. Disc extrusion causing epidural hemorrhage or inflammation is more common in the caudal aspect of the lumbar spine than disc extrusions that do not cause signs of hemorrhage or inflammation (P<0.05) in MR images. In dogs with disc extrusion and associated epidural hemorrhage or inflammation, there was no association between MR imaging features and signalment, the presence or absence of hemorrhage, or pathologic findings. The appearance of the lesion created by disc extrusion with epidural hemorrhage and inflammation encompasses a wide variety of imaging features, likely related to the duration of the hemorrhage and associated inflammatory changes. In 10 of 46 dogs these secondary changes masked identification of the disc extrusion itself in the MR images. An awareness of the variety of MR imaging features of disc extrusion accompanied by extradural hemorrhage or inflammation is important to avoid making an incorrect diagnosis and to facilitate a proper surgical approach. The prognosis of dogs with disc extrusion accompanied by hemorrhage or inflammation does not appear to be different than for dogs with disc extrusion and without imaging signs of epidural hemorrhage or inflammation.